Evidence map›Paper›PMID 41279549›Full record

ArticlebioRxiv : the preprint server for biology2025

Mucosal delivery of influenza antigens using a replication deficient adenovirus supports broadly reactive antibody responses and heterologous viral immunity in the respiratory tract of animals.

Michael D Schultz, Davide Botta, Aaron Silva-Sanchez, Isabella R Cheatwood, Davies Kalange, Sarah M Terapane, Aaron C K Lucander, Fen Zhou, Jobaida Akther, Guang Yang and 13 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Michael D SchultzDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.ORCID 0000-0002-6741-4115
Davide BottaDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.ORCID 0000-0003-3926-0662
Aaron Silva-SanchezDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-1882-2534
Isabella R CheatwoodUndergraduate Immunology Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0009-0008-4271-2774
Davies KalangeDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0009-0006-6337-1599
Sarah M TerapaneUndergraduate Immunology Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0009-0001-0797-7442
Aaron C K LucanderDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.
Fen ZhouDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.
Jobaida AktherDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-3096-3663
Guang YangDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.
Mary E CockerhamDepartment of Biology, Franciscan University of Steubenville, Steubenville, OH 43952, USA.
William O StoverDepartment of Biology, Mercyhurst University, Erie, PA 16546, USA.
John A HallDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.ORCID 0009-0000-1879-8776
Dinesh YadavDepartment of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Douglas M FoxSoutheastern Biosafety Laboratory Alabama Birmingham (SEBLAB), The University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0001-9260-4079
Francisco DominguezSoutheastern Biosafety Laboratory Alabama Birmingham (SEBLAB), The University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-8573-5668
Sixto M LealDepartment of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0001-6939-9572
Jeremy B FooteDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.ORCID 0000-0002-6621-6096
Kevin S HarrodDepartment of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-0780-9470
Troy D RandallImmunology Institute, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-0643-0311
Adrian E RiceImmunityBio, Inc., Culver City, CA 90232, USA.
Elizabeth S GabitzschImmunityBio, Inc., Culver City, CA 90232, USA.
Frances E LundDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham AL 35294 USA.ORCID 0000-0003-3083-1246

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Lalita A. Shevde · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Renee A. Heffron · 1988 to 2026
$84.1M
Regulation of Pathogenic Plasma Cells in Human SLEP01AI125180 · NIAID · EMORY UNIVERSITY · PI Ignacio E. Sanz · 2016 to 2026
$28.2M
Construction/SEBLAB/Regional Biocontainment LaboratoryUC6AI058599 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MARCHASE, RICHARD BANFIELD · 2003 to 2006
$22.0M
Facility Management, Maintenance and Operations CoreUC7AI180255 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Sixto Manuel Leal · 2023 to 2026
$13.3M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Upgrade and operational improvements to the SouthEastern Biosafety Laboratory, Alabama, Birmingham (SEBLAB)G20AI167409 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEAL, SIXTO MANUEL · 2021 to 2022
$7.7M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Protective functions of influenza-specific lung-resident memory B cellsR01AI153413 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2020 to 2025
$3.5M
Identification and characterization of effector memory B cell populations that dominate memory responses to subsequent influenza infection and vaccinationR01AI150740 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LUND, FRANCES E. · 2020 to 2024
$2.9M
Control of B cell differentiation by IFNg induced transcription factorsR01AI110508 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LUND, FRANCES E. · 2014 to 2024
$2.5M
NCI NIH HHS P30 CA013148NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS G20 AI167409NIAID NIH HHS P01 AI125180NIAID NIH HHS P30 AI027767NIAID NIH HHS R01 AI110508NIAID NIH HHS R01 AI150740NIAID NIH HHS R01 AI153413NIAID NIH HHS UC6 AI058599NIAID NIH HHS UC7 AI180255NIDA NIH HHS 75N95020D00005ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Systemically administered influenza vaccines provide strain-limited protection, while influenza infection of the respiratory epithelium supports development of lung resident memory B and T cells and more broadly reactive antibody responses. To test whether local antigen delivery is critical for establishing broad immunity, we directly compared respiratory tract and systemic delivery of influenza antigens to mice and hamsters using a replication-deficient adenovirus serotype 5 vector (Ad5[E1-,E2b-,E3-]). Both immunization routes elicited antibody responses in the lower respiratory tract and antigen-specific B and T cells in the draining lymph node. However, only intranasal immunization established lung-resident memory B and T cells, induced IgA responses in the upper respiratory tract directly at the site of viral entry and supported generation of IgA and IgG antibodies that bound antigenically drifted and distantly related influenza strains, including those of avian origin. Intranasal immunization accelerated viral clearance following heterologous virus challenge and was associated with limited pulmonary inflammation and fibrosis. Thus, intranasal immunization with the immunologically stealthy Ad5[E1-,E2b-,E3-] platform supports respiratory and systemic immunity to divergent influenza strains in the absence of overt lung immunopathology, suggesting that local antigen delivery may be key to development of more broadly protective "universal" flu vaccines.

Indexed as

Adenovirusbroadly reactive antibodiesinfluenza Amucosal B cellsRespiratory tract immunity

Identifiers

PMID41279549
PMCPMC12632757

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.